Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y90-Ibritumomab Tiuxetan Consolidation in High-Risk Follicular Lymphoma
NCT00722930Phase 2Unknown
- Sponsor
- GOTEL
- Start
- Apr 2008
- Primary completion
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by GOTEL. Status: unknown.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00722930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722930.